$127.51
-7.37-5.46%
At Close: -
$127.94
0.430.34%
After Hours: Sep 20, 7:55 PM EDT
15 minutes delayed
Comments
Loading...
Latest news for Novo Nordisk (NYSE:NVO) Stock
Novo Nordisk Stock (NYSE: NVO)
Categories: All
Friday, September 20, 2024
- US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
- Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
- Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial Disappoints
- Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients
- Novo Nordisk shares are trading lower. The co...
- FTC Sues Units Of CVS Health , Cigna , And Un...
- Cantor Fitzgerald Reiterates Overweight on No...
- Novo Nordisk Reports Results From Phase 2a Tr...
- European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Thursday, September 19, 2024
Wednesday, September 18, 2024
Tuesday, September 17, 2024
Monday, September 16, 2024
Wednesday, September 11, 2024
- If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,700 Today
- Roche Says In CT-996 Phase 1 Trial, 4-Week We...
- Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy
- Novo Nordisk shares are trading higher after ...
- Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
Tuesday, September 10, 2024
Monday, September 09, 2024
Friday, September 06, 2024
Thursday, September 05, 2024
Wednesday, September 04, 2024
- Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
- BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
- MHRA Finds No Evidence Supporting Link Betwee...
- EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity